Vivos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update Fourth Quarter Revenue Increased 33% Year-Over-Year While Full Year Revenue Increased 29% Manage

Therapeutics Reports Fourth Quarter and Full Year 2021

Financial Results and Operational Update

Quarter Revenue Increased 33% Year-Over-Year

While Full Year Revenue Increased 29%

to Host Conference Call Today at 5:00 pm ET

RANCH, Colo., March 31, 2022 - Vivos Therapeutics, Inc. ("Vivos"

or the "Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of

innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep

apnea (OSA) and snoring in adults, today reported financial results and operating highlights for the fourth quarter and full year ended

and Operating Highlights

has made substantial progress since our December 2020 initial public offering and achieved a number of key milestones," said R.

Kirk Huntsman, Vivos' Chairman and CEO. "Despite COVID-19 variant resurgences in the middle and latter part of the year,

we generated strong year-over-year revenue growth both for the fourth quarter and full year 2021. Our sales growth reflects increased

market penetration and appliance sales driven by our core of VIPs, as more people adopt The Vivos Method as a treatment for mild to moderate

sleep apnea. It also included revenue generated from new products and services we introduced in 2021, including our Billing Intelligence

Services and MyoCorrect oral myofunctional therapy. Expanding our sources of revenue remains a top priority for us in 2022, even as we

continue to grow revenue from our core business of VIP enrollment and appliances. To that end, at the beginning of this year, we were

able to renegotiate our commercial agreement with SleepImage to lower costs and convert the entire home sleep apnea diagnostic program

from a loss leader aimed primarily at stimulating new case starts with sleep apnea treatment using The Vivos Method to a potential recurring

revenue center. Under the new revenue model with SleepImage, we will lease out the SleepImage ring recorders to VIPs at a fixed price

that includes a full month's worth of diagnostic sleep test reports."

continued, "Vivos also completed a number of significant catalysts to position itself for further growth this year. As of year-end,

approximately 25,000 total patients have been treated with The Vivos Method. We also completed official registration of Vivos products

with Health Canada, providing Canadian dentists complete access to Vivos' services and products. Also of great importance, our

mmRNA oral device was placed on the PDAC list of oral appliances covered by and billable to Medicare. Adding to these developments, we

recently filed a U.S. patent application for proprietary new and enhanced clinical protocols and methods developed within our Vivos Method

for the treatment for OSA. These are all important achievements that leave us well placed for the future."

to strategic relationships, in October we announced a strategic collaboration with Candid Care, a provider of new invisible aligner technology.

Through this relationship, we will collaborate on marketing, sales, lead generation, and the joint development of potential new products.

Vivos also continued to engage with Dental Support Organizations (known as DSOs), whose memberships include thousands of general dental

and specialty practices across North America. During the fourth quarter, we launched the Vivos sleep management program for DSOs, a marketing

and sales initiative whose demand has already exceeded our expectations. We also successfully initiated pilot trials for our Vivos sleep

program involving multiple DSO practices. Further, we are in active contract discussions for additional pilots with several DSO groups

representing close to $3 billion in total annual dental revenue derived from over 1,800 locations. We see great potential in this area

as our DSO market penetration in the U.S. and Canada continues to accelerate in 2022."

what we have already achieved, we are very excited by our future prospects. Complementing these activities and our progress to date,

we will continue to expand our social media marketing outreach to engage more directly with consumers, medical providers and large employers.

By continuing to increase awareness of our products and services, we remain confident this will drive further adoption of The Vivos Method,

which in turn should generate increased VIP enrollment and appliance revenues in 2022 and beyond."

information on Vivos' financial results is included on the attached condensed consolidated balance sheets and statements of operations,

and additional explanations of Vivos' financial performance are provided in the Vivos' Annual Report on Form 10-K for the

twelve months ended December 31, 2021, which will be filed with the Securities and Exchange Commission ("SEC"). The full

10-K report will be available on the SEC Filings section of the Investor Relations section of Vivos' website at https://vivos.com/investor-relations.

December 2021, Vivos announced its official registration with Health Canada, a Minister of Health department responsible for helping

Canadians maintain and improve their health through services and resources. The official registration of Vivos products will aim to provide

patients with a comprehensive, end-to-end solution for OSA patients, which incorporates clinical screening, medical diagnosis and therapy

using Vivos products.

in December, Vivos received acceptance from a Centers for Medicare & Medicaid Services Pricing, Data Analysis and Coding ("PDAC")

contractor for its mmRNA (modified mandibular Repositioning Nighttime Appliance) device for treating mild to moderate OSA and snoring

in adults. This acceptance places the mmRNA device on the PDAC list of oral appliances covered by and billable to Medicare.

to year end, in January 2022, Vivos announced significant increases across several key metrics for its SleepImage Home Sleep Test ring

(or HST), including in particular, for the three-months ended December 31, 2021, versus the three-months ended December 31, 2020: (i)

an 18 times increase in the total number of HSTs given across the VIP network, (ii) a 5.7 times increase in the number of VIPs administering

HSTs and (iii) a 3 times increase in the average number of HSTs being administered per VIP. Vivos believes this performance gain in home

sleep testing allowed it to renegotiate its commercial agreement with SleepImage to lower costs and convert the entire diagnostic program

from a loss leader aimed primarily at stimulating new case starts with sleep apnea treatment using the Vivos Method to a potential recurring

in January, Vivos filed a U.S. patent application related to certain new and enhanced clinical methods and protocols developed within

Vivos' proprietary Vivos Method treatment for OSA. The Vivos Method, inclusive of the Vivos System, seeks to treat dentofacial

abnormalities and/or OSA through a combination of Vivos' proprietary oral appliances and devices as well as proprietary clinical

methods and protocols. This new patent application was based on early field data which revealed an additional 58% average improvement

in Apnea Hypopnea Index (AHI) score reductions in OSA patients who had received treatment with the Vivos Method where the revised clinical

protocols were implemented.

March, Vivos announced a rebranding of its proprietary offering of clinical treatment devices, modalities and protocols, now called The

Vivos Method, to better capture the multiple ways in which Vivos can help independent dentists treat their patients. Vivos also announced

the presentation of new clinical results from retrospective data in patients using The Vivos Method at the 2022 World Sleep Congress

clinical results continue to show the benefits of The Vivos Method, particularly as we enhance and further understand the use and benefits

of our multidisciplinary protocols and devices in patients," continued Mr. Huntsman. "We used to call our offering the Vivos

System, but we believe that didn't do justice to the many options and methods we provide for practitioners to treat their patients

suffering from these debilitating conditions. Our rebrand makes it clearer and easier for providers and patients to understand our offerings

and the manner in which each can contribute to addressing dentofacial and airway abnormalities in a relatable and more approachable way

and to feel secure in proactively asking their dentists or medical providers about The Vivos Method." To learn more about The Vivos

Method, patients can visit Vivos' updated website www.vivos.com to find:

addition to simplifying information for patients visiting the new Vivos website, Vivos now provides dentists looking to tackle OSA and

sleep therapies guidance in becoming a Vivos Integrated Provider. This turnkey program enables dentists to elevate patient services and

care, while also increasing the growth potential for practice revenue and income.

senior management will conduct a conference call today, March 31, 2022 at 5:00 p.m. (Eastern Time) to review the fourth quarter and full

year results as well as provide an overview of the Company's recent milestones and growth strategy.

access the conference call, please dial (888) 256-1007, or for international callers, (720) 543-0214. A replay will be available shortly

after the call and can be accessed by dialing (844) 512-2921, or for international callers, (412) 317-6671. The passcode for the live

call and the replay is 5532262. The replay will be available until April 14, 2022.

live webcast of the conference call can be accessed on Vivos' website at https://vivos.com/investor-relations. An online

archive of the webcast will be available on the Company's website for 30 days following the call.

Vivos Therapeutics, Inc.

Therapeutics Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing a suite of innovative diagnostic

and treatment methods for treating patients with dentofacial abnormalities and / or mild to moderate sleep apnea (OSA) and snoring in

adults. The Vivos Method represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective

solution. The Vivos Method has proven to be effective in approximately 25,000 patients treated worldwide by more than 1,450 trained dentists.

proprietary technologies and protocols that alter the size, shape and position of the tissues that comprise a patient's upper airway,

The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild to moderate OSA, such as

lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program

for Home Sleep Testing in adults and children. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added

services in connection with using the Vivos Method.

more information, visit www.vivos.com.

Note Regarding Forward-Looking Statements

press release, the management presentation referred to herein and statements of the Company's management made in connection therewith

contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E